

REF		CONTENT		Analyzer(s) on which <b>cobas c</b> pack(s) can be used
08056951190	08056951500	Bilirubin Direct Gen.2 (1000 tests)	System-ID 2030 001	<b>cobas c 303, cobas c 503</b>

Materials required (but not provided):

10759350190	Calibrator f.a.s. (12 x 3 mL)	Code 20401	
05117003190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 20391	
05947626190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 20391	
05117216190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 20392	
05947774190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 20392	
10158046122	Precibil (4 x 2 mL)	Code 20306	

## English

### System information

*Jendrassik-Grof method*

**BILD2-J:** ACN 20301

*Doumas method*

**BILD2-D:** ACN 20300

### Intended use

In vitro test for the quantitative determination of direct bilirubin in human serum and plasma on **cobas c** systems.

### Summary

Measurements of direct bilirubin, performed with this assay in human serum and plasma of adults and neonates, are used for the diagnosis of hyperbilirubinemia (such as observed with abnormal destruction of red blood cells, liver diseases, and metabolic disorders, including hepatitis and gallbladder block), and in newborn screening for severe hyperbilirubinemia.

Bilirubin is formed in the reticuloendothelial system during the degradation of aged erythrocytes. The heme portion from hemoglobin and from other heme-containing proteins is removed, metabolized to bilirubin, and transported as a complex with serum albumin to the liver. In the liver, bilirubin is conjugated with glucuronic acid for solubilization and subsequent transport through the bile duct and elimination via the digestive tract. Diseases or conditions which, through hemolytic processes, produce bilirubin faster than the liver can metabolize it, cause the levels of unconjugated (indirect) bilirubin to increase in the circulation. Liver immaturity and several other diseases in which the bilirubin conjugation mechanism is impaired cause similar elevations of circulating unconjugated bilirubin. Bile duct obstruction or damage to hepatocellular structure causes increases in the levels of both conjugated (direct) and unconjugated (indirect) bilirubin in the circulation.<sup>1,2,3,4</sup>

In newborns, several mechanisms lead to an increased bilirubin load, such as increased turnover in fetal red blood cells, reduced bilirubin clearance, and increased enterohepatic circulation of bilirubin. Screening neonates for severe hyperbilirubinemia, especially in newborns with infant jaundice, has been proposed to help preventing chronic bilirubin encephalopathy.<sup>5,6</sup>

### Test principle

Diazo method.<sup>7</sup>

Conjugated bilirubin and  $\delta$ -bilirubin (direct bilirubin) react directly with 3,5 Dichlorophenyl diazonium salt in acid buffer to form the red-colored azobilirubin.

bilirubin + 3,5 DPD  $\longrightarrow$  azobilirubin

The color intensity of the red azo dye formed is directly proportional to the direct (conjugated) bilirubin concentration and can be determined photometrically.

Remark: Under the influence of blue light, e.g. during phototherapy of newborn children, unconjugated bilirubin is partly transformed into a water-soluble isomer called photobilirubin, a substrate for direct bilirubin tests. This fraction is detected by BILD2 and may lead to above-normal results in healthy children.

### Reagents - working solutions

**R1** Phosphoric acid: 85 mmol/L; HEDTA: 4.0 mmol/L; NaCl: 50 mmol/L; detergent; pH 1.9

**R2** 3,5-Dichlorophenyl diazonium: 1.5 mmol/L; pH 1.3

R1 is in position B and R2 is in position C.

### Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

### Reagent handling

Ready for use

### Storage and stability

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 26 weeks

### Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum: Collect serum using standard sample tubes.

Plasma: Li-heparin, K<sub>2</sub>, K<sub>3</sub>-EDTA.

Protect specimens from exposure to light.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

See the limitations and interferences section for details about possible sample interferences.

Stability:<sup>a),8,9</sup> 2 days at 15-25 °C  
7 days at 2-8 °C  
6 months at (-15)-(-25) °C

a) If care is taken to prevent exposure to light  
Freeze only once.

### Materials provided

See "Reagents – working solutions" section for reagents.

**Materials required (but not provided)**

See "Order information" section

General laboratory equipment

**Assay**

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

**Application for serum and plasma****Test definition**

Reporting time	10 min		
Wavelength (sub/main)	800/546 nm		
Reagent pipetting		Diluent (NaCl)	
R1	79 µL	–	
R2	16 µL	–	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (H <sub>2</sub> O)
Normal	4.4 µL	–	–
Decreased	2.2 µL	–	–
Increased	4.4 µL	–	–

For further information about the assay test definitions refer to the application parameters setting screen of the corresponding analyzer and assay.

**Calibration**

Calibrator	S1: H <sub>2</sub> O
	S2: C.f.a.s.
Calibration mode	Linear regression
Calibration frequency	Automatic full calibration
	- after reagent lot change
	Full calibration
	- as required following quality control procedures

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the manual test performance using the Jendrassik-Grof or Doumas method.<sup>10,11</sup>

**Quality control**

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. It is recommended to perform quality control always after lot calibration and subsequently at least every 26 weeks.

Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

**Calculation**

**cobas c** systems automatically calculate the analyte concentration of each sample in the unit µmol/L (mg/dL, mg/L).

Conversion factors:	µmol/L x 0.0585 = mg/dL
	µmol/L x 0.585 = mg/L

**Limitations - interference**

Criterion: Recovery within ± 10 % of initial values at a direct bilirubin concentration of 34.2 µmol/L (2.0 mg/dL).

Hemolysis:<sup>12</sup> No significant interference up to an H index of 25 (approximate hemoglobin concentration: 15.5 µmol/L or 25 mg/dL).

Lipemia (Intralipid):<sup>12</sup> No significant interference up to an L index of 750. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Drugs: No interference was found at therapeutic concentrations using common drug panels.<sup>13,14</sup>

Exception: Phenylbutazone causes artificially low bilirubin results.

Samples containing indocyanine green must not be measured.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.<sup>15</sup>

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

In certain cases specimens may give a direct bilirubin result slightly greater than the total bilirubin result. This is observed in patient samples when nearly all the reacting bilirubin is in the direct form. In such cases the result for the total bilirubin should be reported for both direct bilirubin and total bilirubin values.

**ACTION REQUIRED**

**Special Wash Programming:** The use of special wash steps is mandatory when certain test combinations are run together on **cobas c** systems. All special wash programming necessary for avoiding carry-over is available via the **cobas** link. The latest version of the carry-over evasion list can be found with the NaOHD/SMS/SCCS Method Sheet. For further instructions, refer to the operator's manual.

**Limits and ranges****Measuring range**

*Jendrassik-Grof method*

1.5-291 µmol/L (0.09-17 mg/dL)

*Doumas method*

1.4-236 µmol/L (0.08-14 mg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:2 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 2.

**Lower limits of measurement**

*Jendrassik-Grof method*

*Limit of Blank, Limit of Detection and Limit of Quantitation*

Limit of Blank = 1.0 µmol/L (0.06 mg/dL)

Limit of Detection = 1.5 µmol/L (0.09 mg/dL)

Limit of Quantitation = 3.0 µmol/L (0.18 mg/dL)

The Limit of Blank, the Limit of Detection and the Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from n ≥ 60 measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with a total error of 30 %. It has been determined using low concentration bilirubin samples.

**Lower limits of measurement**

*Doumas method*

*Limit of Blank, Limit of Detection and Limit of Quantitation*

Limit of Blank	= 0.8 µmol/L (0.05 mg/dL)
Limit of Detection	= 1.2 µmol/L (0.07 mg/dL)
Limit of Quantitation	= 1.4 µmol/L (0.08 mg/dL)

The Limit of Blank, the Limit of Detection and the Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from  $n \geq 60$  measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with a total error of 30 %. It has been determined using low concentration bilirubin samples.

### Expected values

#### Jendrassik-Grof method<sup>1</sup>

##### µmol/L

Direct bilirubin  $\leq 5$  µmol/L

##### mg/dL

Direct bilirubin  $\leq 0.30$  mg/dL

An upper limit of 10 µmol/L direct bilirubin for neonates has been cited in the literature, although this has not been confirmed by internal data.<sup>16</sup>

#### Doumas method<sup>17</sup>

##### µmol/L

Direct bilirubin  $\leq 3.4$  µmol/L

##### mg/dL

Direct bilirubin  $\leq 0.20$  mg/dL

An upper limit of 10 µmol/L direct bilirubin for neonates has been cited in the literature, although this has not been confirmed by internal data.<sup>16</sup>

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

### Specific performance data

Representative performance data on the analyzers are given below. These data represent the performance of the analytical procedure itself.

Results obtained in individual laboratories may differ due to heterogenous sample materials, aging of analyzer components and mixture of reagents running on the analyzer.

### Precision

#### Jendrassik-Grof method

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP05-A3 requirements with repeatability ( $n = 84$ ) and intermediate precision (2 aliquots per run, 2 runs per day, 21 days). Results for repeatability and intermediate precision were obtained on the **cobas c 503** analyzer.

Repeatability	Mean µmol/L	SD µmol/L	CV %
PCCC1 <sup>b)</sup>	16.5	0.116	0.7
PCCC2 <sup>c)</sup>	44.1	0.216	0.5
Human serum 1	4.32	0.0810	1.9
Human serum 2	9.76	0.141	1.4
Human serum 3	89.8	0.203	0.2
Human serum 4	139	0.488	0.4
Human serum 5	254	0.756	0.3

#### Intermediate precision

	Mean µmol/L	SD µmol/L	CV %
PCCC1 <sup>b)</sup>	16.5	0.212	1.3
PCCC2 <sup>c)</sup>	44.1	0.573	1.3
Human serum 1	4.31	0.107	2.5
Human serum 2	9.76	0.241	2.5
Human serum 3	89.8	0.615	0.7
Human serum 4	139	2.23	1.6
Human serum 5	254	2.42	1.0

b) PreciControl ClinChem Multi 1

c) PreciControl ClinChem Multi 2

#### Doumas method

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP05-A3 requirements with repeatability ( $n = 84$ ) and intermediate precision (2 aliquots per run, 2 runs per day, 21 days). Results for repeatability and intermediate precision were obtained on the **cobas c 503** analyzer.

#### Repeatability

	Mean µmol/L	SD µmol/L	CV %
PCCC1 <sup>b)</sup>	13.2	0.0838	0.6
PCCC2 <sup>c)</sup>	35.6	0.146	0.4
Human serum 1	3.23	0.0673	2.1
Human serum 2	8.64	0.0899	1.0
Human serum 3	57.2	0.179	0.3
Human serum 4	109	0.393	0.4
Human serum 5	195	0.512	0.3

#### Intermediate precision

	Mean µmol/L	SD µmol/L	CV %
PCCC1 <sup>b)</sup>	13.2	0.175	1.3
PCCC2 <sup>c)</sup>	35.9	0.429	1.2
Human serum 1	3.32	0.0945	2.8
Human serum 2	8.64	0.176	2.0
Human serum 3	57.8	0.421	0.7
Human serum 4	110	1.89	1.7
Human serum 5	195	1.98	1.0

The data obtained on **cobas c 503** analyzer(s) are representative for **cobas c 303** analyzer(s).

### Method comparison

#### Jendrassik-Grof method

Bilirubin values for human serum and plasma samples obtained with the Roche BILD2 reagent on a **cobas c 503** analyzer (y) were compared with those determined using the corresponding reagent on a **cobas c 501** analyzer (x).

Sample size ( $n$ ) = 582

Passing/Bablok<sup>18</sup>

$$y = 1.001x + 0.646 \text{ µmol/L}$$

$$\tau = 0.965$$

Linear regression

$$y = 0.987x + 1.28 \text{ µmol/L}$$

$$r = 1.000$$

The sample concentrations were between 1.50 and 288 µmol/L.

Bilirubin values for human serum and plasma samples obtained with the Roche BILD2 reagent on a **cobas c 303** analyzer (y) were compared with those determined using the corresponding reagent on a **cobas c 501** analyzer (x).

Sample size ( $n$ ) = 64

Passing/Bablok<sup>18</sup>

Linear regression

# BILD2

## Bilirubin Direct Gen.2

$$y = 0.988x + 1.02 \mu\text{mol/L}$$

$$\tau = 0.952$$

$$y = 0.938x + 2.53 \mu\text{mol/L}$$

$$r = 0.999$$

The sample concentrations were between 1.50 and 276  $\mu\text{mol/L}$ .

### Doumas method

Bilirubin values for human serum and plasma samples obtained with the Roche BILD2 reagent on a **cobas c 503** analyzer (y) were compared with those determined using the corresponding reagent on a **cobas c 501** analyzer (x).

Sample size (n) = 66

Passing/Bablok<sup>18</sup>

Linear regression

$$y = 1.001x + 0.481 \mu\text{mol/L}$$

$$\tau = 0.966$$

$$y = 0.985x + 1.22 \mu\text{mol/L}$$

$$r = 0.999$$

The sample concentrations were between 1.49 and 231  $\mu\text{mol/L}$ .

Bilirubin values for human serum and plasma samples obtained with the Roche BILD2 reagent on a **cobas c 303** analyzer (y) were compared with those determined using the corresponding reagent on a **cobas c 501** analyzer (x).

Sample size (n) = 62

Passing/Bablok<sup>18</sup>

Linear regression

$$y = 0.985x + 0.716 \mu\text{mol/L}$$

$$\tau = 0.928$$

$$y = 0.941x + 1.81 \mu\text{mol/L}$$

$$r = 0.999$$

The sample concentrations were between 1.40 and 222  $\mu\text{mol/L}$ .

### References

- McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 21st ed. Saunders Elsevier, 2007:1405.
- Sticova E, Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol 2013;19(38):6398-6407.
- Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112(1):18-35.
- Newsome PN, Cramb R, Davidson SM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018;67(1):6-19.
- American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114(1):297-316.
- Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants: Joint Recommendation of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2017;64(1):154-168.
- Malloy HT, Evelyn KA. The determination of bilirubin with the photoelectric colorimeter. J Biol Chem 1937;119:481-490.
- Quality of Diagnostic Samples, Recommendations of the Working Group on Preanalytical Quality of the German Society for Clinical Chemistry and Laboratory Medicine, 3rd completely revised ed. 2010.
- Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev. 2: Jan 2002.
- Jendrassik L, Grof P. Vereinfachte photometrische Methode zur Bestimmung des Bilirubins. Biochem Z 1938;297:81-89.
- Doumas BT, Perry BW, Jendrzyczak B, et al. Pitfalls in the American Monitor Kit Methods for Determination of Total and Direct Bilirubin. Clin Chem 1982;28(11):2305-2308.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Soldin JS, Brugnara C, Wong EC. Pediatric Reference Intervals. AACC Press, 5th ed., 2005.
- Balistreri WF, Shaw LM. Liver function. In: Tietz NW, ed. Fundamentals of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders 1987;729-761.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

### Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see [navifyportal.roche.com](http://navifyportal.roche.com) for definition of symbols used):

 CONTENT

Contents of kit



Volume for reconstitution

 GTIN

Global Trade Item Number

Rx only

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

COBAS, NAVIFY and PRECICONTRON are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2023, Roche Diagnostics

 0123



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
[www.roche.com](http://www.roche.com)

+800 5505 6606

